Mabel Perez
General Practice · Houston, TXNPI 1578595369
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,344 and has fallen 95.5% since, to $60 in 2025. Among general practice clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$426
- Lilly USA, LLC$422
- Novo Nordisk$397
- Boehringer Ingelheim$212
- Amarin Pharma, Inc.$204
- Pfizer$198
- plus $776 from 14 others
What the payments were for
- Food & beverage$2,624100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $426 |
| Lilly USA, LLC | 17 | $422 |
| Novo Nordisk | 30 | $397 |
| Boehringer Ingelheim | 7 | $212 |
| Amarin Pharma, Inc. | 10 | $204 |
| Pfizer | 8 | $198 |
| Exact Sciences | 8 | $158 |
| Merck | 3 | $130 |
| Alkermes, Inc. | 4 | $78 |
| Astellas Pharma US Inc | 3 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Amgen | 3 | $55 |
| Abbott | 2 | $46 |
| AbbVie | 2 | $45 |
| Johnson & Johnson | 2 | $32 |
| Phadia US Inc. | 2 | $31 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,635 in reported general payments places this provider in the 90th percentile of 8,074 general practice providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,349 |
| Atorvastatin Calcium | 67 | $824 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $696 |
| Valsartan | 18 | $601 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 19 | $503 |
| Metoprolol Succinate | 31 | $490 |
| Pravastatin Sodium | 13 | $457 |
| Levothyroxine Sodium | 42 | $443 |
| Metformin Hcl ErMetformin Hcl | 24 | $442 |
| Gabapentin | 30 | $421 |
| Ibandronate Sodium | 12 | $400 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 20 | $391 |
| Rosuvastatin Calcium | 28 | $354 |
| Losartan Potassium | 21 | $332 |
| Amlodipine Besylate | 25 | $265 |
Paid to pharmacies, not to this prescriber.
Other general practice in Houston
- Kathleen Szelei-StevensHouston$253K
- Zsolt GaramiHouston$111K
- Scott ColemanHouston$87K
- Rispba McCray-GarrisonHouston$70K
- Piya GandhiHouston$36K
- Terri AlaniHouston$30K
- Demetris GreenHouston$26K
- Steven XueHouston$19K
- Carol DupuisHouston$16K
- Rosita HamidiHouston$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.